Cargando…
P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)
Autores principales: | Palandri, F., Ross, D. M., Cochrane, T., Tate, C., Lane, S. W., Larsen, S. R., Gerds, A. T., Halpern, A. B., Shortt, J., Rossetti, J. M., Pettit, K. M., Liang, J., Mead, A., Marchetti, M., Vannucchi, A., Wilson, A., Göthert, J. R., Hanna, M., Jones, A., Peppe, J., Natsoulis, G., McClure, T., Hong, W.-J., Stevenson, W. S., Harrison, C. N., Talpaz, M., Vianelli, N., Rienhoff, H. Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429289/ http://dx.doi.org/10.1097/01.HS9.0000847000.38667.91 |
Ejemplares similares
-
P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS
por: Gill, H., et al.
Publicado: (2022) -
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015) -
Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996) -
Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018) -
Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)